Seller record · Telehealth service

Ozari Health

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S5, analytical documentation: No certificate of analysis or lot document is published on the product pages, the answers page, the terms or the policies. 1 more criterion also fails; see the table below.

At a glance

Ozari HealthTelehealth service

6/8criteria passed

Price: Semaglutide $175 billed monthly, or $86 a month on a 3-month starter plan for first-time users
Sells: compounded semaglutide, compounded tirzepatide, sermorelin injection, and 3 more
FDA letters: None on file

Visit Ozari Health See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling compounded semaglutide and tirzepatide on monthly, quarterly, semi-annual and annual plans, with sermorelin, NAD+, glutathione and Lipo-C injections. It names two filling pharmacies and prints no street address.

Operating entity Ozari LLC

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Ozari Health's website; Ozari Health's terms
S2	Prescription gating	PASS	Ozari Health's startglp page on its app site
S3	Pharmacy identification	PASS	Ozari Health's semaglutide product page; Ozari Health's tirzepatide product page
S4	Compounding disclosure	PASS	Ozari Health's tirzepatide product page; Ozari Health's GLP-1 FAQ
S5	Analytical documentation	FAIL	Ozari Health's GLP-1 FAQ; Ozari Health's terms
S6	Business address	FAIL	Ozari Health's terms; Ozari Health's privacy page; Ozari Health's hipaa page; Ozari Health's refund policy
S7	Price disclosure	PASS	Ozari Health's semaglutide product page; Ozari Health's tirzepatide product page; Ozari Health's NAD+ plus page; Ozari Health's sermorelin page
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed physician reviews each intake and decides whether treatment is appropriate, and the terms bar the purchase of a prescription product until a consultation with one of the providers is complete.Source: Ozari Health's website; Ozari Health's terms.

S2PASSThe start button opens a health questionnaire whose first screen asks why the buyer wants to lose weight.Source: Ozari Health's startglp page on its app site.

S3PASSThe answers on the semaglutide and tirzepatide pages name two 503A compounding pharmacies: Hallandale Pharmacy in Fort Lauderdale, FL, and VialsRx. No state is printed for VialsRx.Source: Ozari Health's semaglutide product page; Ozari Health's tirzepatide product page.

S4PASSCompounded medications are not FDA-approved and have not been evaluated by FDA, printed in the footer of every page and in the answers on each GLP-1 page.Source: Ozari Health's tirzepatide product page; Ozari Health's GLP-1 FAQ.

S5FAILNo certificate of analysis or lot document is published on the product pages, the answers page, the terms or the policies.Source: Ozari Health's GLP-1 FAQ; Ozari Health's terms.

S6FAILNo street address is printed for Ozari LLC. The terms, the privacy policy, the HIPAA notice and the refund policy give only an email address, and the footer adds a phone number.Source: Ozari Health's terms; Ozari Health's privacy page; Ozari Health's hipaa page; Ozari Health's refund policy.

S7PASSCompounded semaglutide at $175 billed monthly, $145 a month on a quarterly plan billed $435, $120 a month semi-annually and $99 a month on an annual plan billed $1,188, or $86 a month on a 3-month starter plan for first-time GLP-1 users billed $257. Compounded tirzepatide at $235 billed monthly, $199 a month quarterly, $175 semi-annually and $140 on an annual plan, or $125 a month on the starter plan billed $375. NAD+ at $199 a month, sermorelin at $159, Lipo-C at $149 and glutathione at $100, each lower on a quarterly plan.Source: Ozari Health's semaglutide product page; Ozari Health's tirzepatide product page; Ozari Health's NAD+ plus page; Ozari Health's sermorelin page.

S8PASSNo FDA warning letter names Ozari Health or Ozari LLC, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, sermorelin injection, NAD+ injection, glutathione injection, Lipo-C injection.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide Who sells sermorelin Who sells NAD+Who sells glutathione

Visit Ozari Health

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.